The laboratory of Nathan Karin focuses on three major subjects: The first is exploring the biological basis of self- non-self recognition by the immune system, in particular how immunological tolerance is actively maintained? The lead research model of autoimmune disease, in which the immune system attacks self-components, is a mouse model for an autoimmune disease of the central nervous system named Multiple Sclerosis (MS). The lab also explores its key findings in experimental models of two other diseases: Inflammatory Bowl’s disease (IBD), including Crohn’s and Colitis. and type I diabetes. In these studies the lab uses cutting-edge molecular and cellular techniques. The second major subject of research is exploring the role of a group of small chemotactic cytokines named chemokines in the regulation of leukocyte migration and function in autoimmune diseases and also in cancer diseases. The third path of research in the lab focuses on exploring the genetic basis of several auto-inflammatory diseases, in which due to gene regulation defects the immune system damages self-components. Beyond exploring the mechanistic basis of these diseases the lab aims at developing novel tools for pharmacodynamics and personalized based therapy of these diseases.
The laboratory of Nathan Karin explores the mechanistic basis of immunological tolerance and develop novel therapeutic strategies. Click to read more >>
Nathan Karin is a world-leading scientist in molecular and cellular immunology, his major discovery led to the development of the currently leading drug for Multiple Sclerosis.
Prof. Nathan Karin and his team have published dozens of papers in leading journals over the years. Click to view a list of key publications.